Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00091871 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 307 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor Study description expanded, about 2 words
  2. Minor 27 versions Re-verified since May 17, 2025, no change to tracked fieldsv280-v306
  3. Minor Study Status, Study Descriptionv279
  4. Minor 21 versions Re-verified since Jun 28, 2024, no change to tracked fieldsv258-v278
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies. This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration. Participants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.
Trial Details
NCT Number NCT00091871
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)
Eosinophilia, Hypereosinophilic Syndrome
Related terms Eosinophilia, Hypereosinophilic Syndrome
Enrollment 50 participants
Start Date
Updated on ClinicalTrials.gov